Targeting human lung adenocarcinoma with a suppressor of mitochondrial superoxide production

N Dias Amoedo, L Dard, S Sarlak… - Antioxidants & Redox …, 2020 - liebertpub.com
N Dias Amoedo, L Dard, S Sarlak, W Mahfouf, W Blanchard, B Rousseau, J Izotte…
Antioxidants & Redox Signaling, 2020liebertpub.com
Aims: REDOX signaling from reactive oxygen species (ROS) generated by the mitochondria
(mitochondrial reactive oxygen species [mtROS]) has been implicated in cancer growth and
survival. Here, we investigated the effect of 5-(4-methoxyphenyl)-3H-1, 2-dithiole-3-thione
(AOL), a recently characterized member of the new class of mtROS suppressors (S1QELs),
on human lung adenocarcinoma proteome reprogramming, bioenergetics, and growth.
Results: AOL reduced steady-state cellular ROS levels in human lung cancer cells without …
Aims: REDOX signaling from reactive oxygen species (ROS) generated by the mitochondria (mitochondrial reactive oxygen species [mtROS]) has been implicated in cancer growth and survival. Here, we investigated the effect of 5-(4-methoxyphenyl)-3H-1,2-dithiole-3-thione (AOL), a recently characterized member of the new class of mtROS suppressors (S1QELs), on human lung adenocarcinoma proteome reprogramming, bioenergetics, and growth.
Results: AOL reduced steady-state cellular ROS levels in human lung cancer cells without altering the catalytic activity of complex I. AOL treatment induced dose-dependent inhibition of lung cancer cell proliferation and triggered a reduction in tumor growth in vivo. Molecular investigations demonstrated that AOL reprogrammed the proteome of human lung cancer cells. In particular, AOL suppressed the determinants of the Warburg effect and increased the expression of the complex I subunit NDUFV1 which was also identified as AOL binding site using molecular modeling computer simulations. Comparison of the molecular changes induced by AOL and MitoTEMPO, an mtROS scavenger that is not an S1QEL, identified a core component of 217 proteins commonly altered by the two treatments, as well as drug-specific targets.
Innovation: This study provides proof-of-concept data on the anticancer effect of AOL on mouse orthotopic human lung tumors. A unique dataset on proteomic reprogramming by AOL and MitoTEMPO is also provided. Lastly, our study revealed the repression of NDUFV1 by S1QEL AOL.
Conclusion: Our findings demonstrate the preclinical anticancer properties of S1QEL AOL and delineate its mode of action on REDOX and cancer signaling.
Mary Ann Liebert